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Abstract Vertebral fracture (VF) is the most common osteo-
porotic fracture and is associated with high morbidity and
mortality. Conservative treatment combining antalgic agents
and rest is usually recommended for symptomatic VFs. The
aim of this paper is to review the randomized controlled trials
comparing the efficacy and safety of percutaneous
vertebroplasty (VP) and percutaneous balloon kyphoplasty
(KP) versus conservative treatment. VP and KP procedures
are associated with an acceptable general safety. Although the
case series investigating VP/KP have all shown an outstand-
ing analgesic benefit, randomized controlled studies are rare
and have yielded contradictory results. In several of these
studies, a short-term analgesic benefit was observed, except
in the prospective randomized sham-controlled studies. A
long-term analgesic and functional benefit has rarely been
noted. Several recent studies have shown that both VP and
KP are associated with an increased risk of new VFs. These
fractures are mostly VFs adjacent to the procedure, and they
occur within a shorter time period than VFs in other locations.
The main risk factors include the number of preexisting VFs,
the number of VPs/KPs performed, age, decreased bone min-
eral density, and intradiscal cement leakage. It is therefore
important to involve the patients to whom VP/KP is being
proposed in the decision-making process. It is also essential to
rapidly initiate a specific osteoporosis therapy when a VF
occurs (ideally a bone anabolic treatment) so as to reduce
the risk of fracture. Randomized controlled studies are
necessary in order to better define the profile of patients who
likely benefit the most from VP/KP.
Keywords Kyphoplasty . Osteoporosis . Vertebral fracture .
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Introduction
VF is the most common complication of osteoporosis. It is
associated with increased morbidity and mortality and, in a
minority of patients, with considerable pain. It is estimated
that 3 % of all VFs are pathological, 14 % are trauma-related,
and 83% are osteoporotic [1]. For women at the age of 50, the
residual risk for VF is 32 % [2]. In both the USA and Europe,
annual risk increases with age, ranging from 0.4–0.6 % in
women who are between 50 and 54 to 1.2–1.3 % in those who
are between 65 and 69, and to 2.9–3.8 % in those who are 85
or older [3, 4].
VF is widely underdiagnosed in all countries. The IM-
PACT study showed this for North America, South America,
Europe, Australia, and South Africa [5]. However, the under-
diagnosis may be related to a problem of qualitative or quan-
titative definition of VF. Nearly 70 % of VFs are not clinically
recognized as such because they are asymptomatic or only
slightly symptomatic, or they are not diagnosed [6, 7].
Symptomatic VFs cause as many days of confinement to
bed and functional incapacity as hip fractures, if not more [8].
Quality of life can be very much lowered following symp-
tomatic or asymptomatic VF [9-12]: height loss and kyphosis,
besides physical pain, symptoms include sleeping disorders,
fear of a fall that may lead to new fractures, loss of confidence,
and psychological disorders ranging from anxiety to depres-
sion. When serious, thoracolumbar static disorders may cause
a reduction in respiratory function (restrictive syndrome) as
well as digestive disorders (early satiety) accompanied by loss
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of weight. The simple movements of daily life become more
and more difficult. All these problems may lead to isolation, a
situation that is much feared in geriatric medicine. Moreover,
the VF increases the risk of mortality. The consequences of
VF, especially the mortality, increase with the number and the
severity of VF.
The presence of a VF increases the risk of new vertebral and
non-vertebral fractures. In the Rochester study, the cumulated
incidence of suffering a new fracture (or several fractures)
during the year following the first VF was around 20 %; at
10 years, cumulated risk was more than 70 % [13]. The pres-
ence of a VF increases the risk of newVFs from 3 to 12 and the
risk of non-vertebral fractures from 1.5 to 4 [6, 13-17]. The
more severe the VF is, and the more VFs there are, the more the
risk of vertebral and non-vertebral fracture recurrence increases
[18]. In the MORE study, over the 3 years, the risk of VF
recurrence increased from 10.5 % in the presence of a prior VF
of grade I to 38.1 % when the VF was grade III [19].
Many antiresorptive and anabolic therapies have shown effi-
cacy in lowering the risk of VF recurrence in randomized trials
against placebo. The percent of fracture reduction given below
should not be compared. SERMs, oral bisphosphonates, and
strontium ranelate have been reported to lower this risk by
around 50 %; zoledronic acid, denosumab, and teriparatide by
nearly 70 %. The antifracture effect is obtained after 6 to
12 months. These therapies are also particularly efficacious for
reducing the risk of multiple VFs, and so may lower the ensuing
pain and morbidity. Of the common osteoporosis therapies,
teriparatide was the only one to have shown efficacy in reducing
back pain comparedwith other osteoporosis therapies or placebo
[20-22]. As the risk of subsequent fractures is very high during
the first months that follow a VF, and as the therapies are rapidly
efficacious, it is essential to initiate these therapies without delay.
Patients receiving an osteoporosis therapymust have a sufficient
intake of calcium (around 1,200 mg/day) and vitamin D (around
800–1,000 IU/day or 20–25 μg/day). This intake optimizes the
effect of osteoporosis treatments and improves musculoskeletal
health while lowering the risk of falls and fractures.
Treating a symptomatic VF often requires immobilization
and antalgic agents. The role of contention on pain is contro-
versial, partly because of a lack of data. Acute treatment only
applies to symptomatic fractures. Nonsteroidal analgesics at
reasonably high doses are the treatment of choice. Morphine
derivatives may be included in case of failure, and calcitonin
may be used for 4 weeks [23]. Both confinement to bed and the
use of certain analgesics over long periods are associated with
several side effects that are particularly worrying in the elderly,
such as deconditioning, respiratory superinfection, impaired
balance, and increased risk of falling. To avoid these side
effects, or when pain cannot be controlled, minimally invasive
treatment may be suggested. VP and KP are proposed to relieve
VF-related pain; KP also enables vertebral height to be partially
restored and secondary kyphosis to be limited.
Method
The authors conducted a MEDLINE search using relevant
search terms including osteoporosis, osteoporotic vertebral
compression fracture, kyphoplasty, and vertebroplasty. This
article is a review of the randomized controlled studies that
have been published comparing VP or KP with conservative
treatment, or VPwith KP following osteoporotic VF (Table 1).
Because there are not many randomized studies on this sub-
ject, case series and retrospective and prospective cohort
analyses were included whenever they provided pertinent
additional information. In order to limit the length of this
article, we based our research on literature reviews as well as
on meta-analyses of good quality [24-26].
First, we summarized the historical and technical aspects of
VP and KP. Second, the articles were analyzed in terms of
benefits: pain relief, quality of life, functional improvement,
and increase of vertebral height. Third, we analyzed the side
effects and complications of VP and KP.
Vertebroplasty and kyphoplasty: history and technical
aspects
The first VPs were performed in 1984 in order to treat symptom-
atic vertebral angiomas [27]. Their use was next extended to the
treatment of symptomatic vertebral metastases, and then to trau-
matic VFs. It was at the beginning of the 1990s that the procedure
was used in the analgesic treatment of osteoporotic VFs.
VP involves the injection of a radiopaque cement under X-
ray guidance, usually a polymethylmethacrylate resin
(PMMA) [28]. The procedure is performed via the
transpedicular approach (ideally bilaterally) through a trocar
under local or general anesthesia. PMMA is a two-component
(liquid/powder) resin. It is combined with a contrast agent so
that the procedure can be followed. After between 8 and
10min, the PMMA polymerizes and hardens, a process which
is accompanied by an exothermic reaction reaching up to
around 75 °C in the center of the vertebra. The analgesic effect
of VP is attributed to several factors, including the thermal
reaction, as well as the consolidation and stabilization of the
fracture. VP requires that the resin be injected at relatively
high pressure because of its low viscosity [29]. This is accom-
panied by a high risk of cement leakage. It is often said that
VP must be performed fairly soon after a VF to obtain the
analgesic effect. However, authors have shown analgesic ben-
efits for VFs up to 1 year after their occurrence [30, 31].
Nieuwenhuijse et al. analyzed the relationship between the
fracture date and VP efficacy in 115 patients who had under-
gone 216 VPs [31]. The mean time from fracture to VP was
6.0±2.9 months. The authors concluded that the analgesic
benefits and improvement in quality of life obtained were
independent of the length of time between the VF and VP.
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KP was developed to improve VP [32], using the same
approach route as for VP. An inflatable balloon is inserted via
the trocar, allowing a void to be made. The balloon is then
removed, and the cement is injected at lower pressure into the
void. The theoretical advantages are a lowering of the risk of
cement leakage and (partial) restoration of anterior and middle
vertebral wall height. KP was approved by the US Food and
Drug Administration in 1998.
Before performing VP/KP, magnetic resonance imaging
(MRI) must be conducted to verify that the posterior wall is
intact. Table 2 summarizes the usual contraindications to VP/
KP [33]. VP takes less time than KP and costs less. These
highly promising procedures were very popular between the
years 2000 and 2009. They are mainly performed by radiolo-
gists, orthopedists, and neurosurgeons. In the USA, the num-
ber of VPs performed increased from around 14,000 in 2001
to nearly 30,000 in 2005, and the number of KPs from around
43,000 in 2006 to more than 50,000 in 2008 [34]. Following
the publication of reports that called into question the clinical
benefit of VP in 2009, the number of VPs and KPs performed
decreased by 10 % [34-36].
Vertebroplasty and kyphoplasty: efficacy
Efficacy of vertebroplasty
The first publications that included case reports and case series
all concluded that VP had an outstanding analgesic effect in
around 90 % of patients. In 2009, a large literature review of
VP and KP for osteoporotic VFs was published [25]. The
results of that review suggested that there were analgesic and
functional benefits observed during the first 3 months follow-
ing VP compared with conventional medical treatments. Of
the 74 studies analyzed, 70 were case series. There was only
one randomized controlled study comparing VP with medical
treatment [37], and there were three prospective non-
randomized controlled studies comparing the two treatment
strategies [38-40]. The Vertos randomized controlled study
included 34 patients, 18 in the VP group and 16 in the optimal
medical therapy (OMT) group [37]. Analysis at day 1 and at
week 2 showed an analgesic and functional benefit in the VP
group. Due to the low number of patients and high rate of
switching from the OMT group to the VP group, no conclu-
sions could be drawn regarding potential long-term benefits.
The three non-randomized controlled studies confirmed these
rapid benefits for the patients who had undergone VP. Dia-
mond et al. compared 55 patients treated by VP with 24
receiving OMT [38]. The analgesic and functional benefits
observed at the beginning were no longer significant after 1.5,
6, and 12months. Alvarez et al. compared 101 patients treated
by VP with 27 receiving OMT [39]. In the VP group, the
analgesic benefit was significant at 3 and 6 months; the
functional benefit was significant at 3 months. At 12 months,
there was no longer any difference between the two groups. In
a second trial, Diamond et al. prospectively followed up 88
patients treated by VP and 38 who received OMT [40]. The
analgesic and functional benefits were significant in the VP
group at 6 weeks, but there was no difference at 1 and 2 years.
The other 70 case series all reported an immediate analgesic
benefit [25]. Thus, there was a trend in the literature
supporting a rapid analgesic and functional benefit with VP
when performed for osteoporotic VF management. Also in
2009, but not included in the meta-analysis of McGirt et al.,
Rousing et al. published a randomized controlled study,
which, however, exhibited methodological shortcomings re-
garding pain evaluation [41]. The VP group had an immediate
analgesic benefit within 12 to 24 h of the procedure that was
significantly greater than that of the control group. The au-
thors reported two new VFs in the VP group, whereas there
were none in the control group, after 3 months. Follow-up at 3
and 12 months showed no difference in terms of analgesic
benefits between the two groups [41, 42].
There was controversy when two prospective randomized
sham-controlled studies were published in the New England
Journal of Medicine in 2009 [35, 36]. The patients in both the
VP and control groups were managed under the same condi-
tions: treatment in the interventional radiology room, local
anesthesic infiltration of the posterior longitudinal ligament,
and cement prepared beside the patients. A sham insertion of a
trocar into the vertebra was performed in the control group;
only the VP group was injected with cement. Buchlinder et al.
enrolled 78 patients who had suffered one or two painfulMRI-
confirmed osteoporotic VFs within the previous 12 months
with unfavorable clinical evolution [35]. The patients were
stratified according to the duration of symptoms (<6 weeks or
≥6 weeks). They were evaluated at 1 week and at 1, 3, and
6 months. The primary outcome was overall pain on a scale of
0 to 10. VP showed no benefit at any time compared with the
Table 2 Usual contraindications to percutaneous vertebroplasty or
kyphoplasty
Osteoporotic vertebral fracture related contraindications
• Fracture with posterior wall defect
• Severe vertebral body collapse (vertebra plane)
• Prophylaxis with no evidence of acute fracture
• Asymptomatic stable fracture
Other vertebral diseases related contraindications
• Osteomyelitis or spondylodiscitis
• Tumor extension into epidural space
General contraindications
• Uncorrected coagulation disorders
• Allergy to any required component
• Pregnancy
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control group in terms of pain, functional status, quality of life,
or even perceived improvement. For example, at 3 months,
the mean reduction in the pain score was 2.6±2.9 in the VP
group and 1.9±3.3 in the control group (adjusted between-
group difference, 0.6; 95 % CI, –0.7 to 1.8). Kallmes et al.
enrolled 131 patients who had between one and three painful
CT- or MRI-confirmed osteoporotic VFs for less than
12 months with unfavorable clinical evolution [36]. The pri-
mary outcomes were scores on the modified Roland-Morris
Disability Questionnaire (RDQ) and overall pain on a scale of
0 to 10 at 1 month. There was an immediate improvement with
regard to pain in both groups. At 1 month, there was no
significant difference between the VP and control groups in
either the RDQ score (difference 0.7; 95 % CI, −1.3 to 2.8;
P=0.49) or the pain score (difference 0.7; 95 % CI, −0.3 to 1.7;
P=0.19). At 3months, there was a high rate of crossover (51%)
in the control group. It was therefore not possible to evaluate
VP’s benefit at 3 or 6 months. Despite the negative results of
these two prospective randomized sham-controlled studies, sev-
eral authors voiced objections, pointing out that VP should be
reserved for patients with acute VF of recent onset (<6 weeks),
for those who have severe pain, or for those in whom MRI has
shown edema to be present [43, 44]. In response to some of
these objections, a meta-analysis of these two studies was con-
ducted using the individual data of the 209 patients [45]. The
analyses took into account the date of the VF (≤ or >6 weeks)
and severity of pain on a scale of 10 (≥ or <8). For the patients
with recent pain (≤6 weeks), between-group differences at
1 month for pain and disability scores were 0.1 (95 % CI, –1.4
to 1.6) and 0.2 (95 % CI, –3.0 to 3.4), respectively. For patients
with severe pain (≥8), between-group differences at 1 month for
pain and disability scores were 0.3 (95%CI, –0.8 to 1.5) and 1.4
(95 % CI, –1.2 to 3.9), respectively. At the beginning of the
study, 68 % of patients in the different groups were on opioids.
Surprisingly, at 1 month, there were more VP patients than
control patients on opioids (64 versus 46 %; P=0.018). The
authors of thismeta-analysis concluded that VP did not offer any
benefit, not even in the subgroups of patients who theoretically
should have benefited the most.
VERTOS II, an open-label randomized trial, was published
in 2010 [46]. The authors enrolled 202 patients who had a VF
and met strict criteria: pain for less than 6 weeks, a visual
analogue scale (VAS) score ≥5, and edema on MRI. The
patients who were randomized into the VP group had better
pain control at 1 month and 1 year than the control group. The
difference between the groups in the reduction of mean VAS
score from baseline was 2.6 (95 % CI, 1.7–3.4; P <0.0001) at
1 month and 2.0 (95 % CI, 1.1–2.8, P <0.0001) at 1 year. One
randomized controlled study involving 82 patients (refractory
to analgesic therapy for>4 weeks and <1 year) showed a
highly significant improvement in pain relief for 6 months
and quality of life for at least 36 months [47]. All patients in
the OMT group were treated with analgesic agents, calcitonin
and alendronate. After 2 years of follow-up, the incidence of
new VFs in the OMT group was higher than in the VP group
(13.3 versus 2.2 %; P <0.01). The VP was made via a unilat-
eral parapedicular approach in 87.5 % of patients. The cement
leakage was only 14 % (including intervertebral disc, epidural
and paravertebral space). Ten patients in the OMT group with
persistent pain and low level of quality of life 1 year after the
study started crossed over to VP. They had a significant pain
relief. An open-label randomized trial published in 2012 en-
rolled 125 patients [48]. There was a significant decrease in
VAS in both groups. However, at 2 months, VAS improve-
ment was greater in the VP group than in the control group
(mean differences 1.59±0.42 versus 3.07±0.45, P =0.017).
The quality of life questionnaire of the European Foundation
for Osteoporosis (Qualeffo-41) was significantly improved in
the VP group at the evaluation time points, whereas the
improvement in the control group was significant only after
6 months. There were no differences between the two groups
at 1 year, be it for VAS or Qualeffo-41. However, there were
significantly more new VFs in the VP group (OR 2.78; 95 %
CI, 1.02–7.62, P =0.046).
Efficacy of kyphoplasty
An initial meta-analysis published in 2006, which was mainly
based on case series, included 26 studies involving 1,490
patients who had undergone 2,643 KPs [49]. The analysis
results documented a mean VAS reduction of −5.1, an aug-
mentation of anterior vertebral wall height of 13.4 %, a reduc-
tion in kyphosis as measured by Cobb’s angle of −7.7 %, and
an improvement in functional indices of +20 %. However, the
authors emphasized the methodological shortcomings of these
studies and the insufficient follow-up of patients. By 2009, 35
studies pertaining to KP had been published [25]. Thirty-three
studies were case series, and all concluded that there was a
rapid analgesic effect. There was no randomized controlled
study, and only one prospective non-randomized controlled
study, which was published in two parts [50, 51]. Forty
patients treated by KP were compared with 20 patients receiv-
ing conventional medical treatment. There was an analgesic
benefit and functional improvement at 3, 6, and 12 months in
the KP group. The Fracture Reduction Evaluation Study
(FREE) has been the only randomized controlled study to
have compared KP with conventional medical treatment
[52]. A total of 300 patients were randomized after a mean
6-week period following a VF (osteoporosis-related in 95 %
of cases). The primary outcome was the difference in change
from baseline to 1 month in the short-form SF-36 physical
component summary (PCS) score (scale 0–100). Mean SF-36
PCS score improved by 7.2 points (95 % CI, 5.7–8.8), from
26.0 at baseline to 33.4 at 1 month, in the KP group, and by
2.0 points (95 % CI, 0.4–3.6), from 25.5 to 27.4, in the control
group (difference between groups 5.2 points, 2.9–7.4; P <
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0.0001). This benefit for the KP group was still present at
1 year. The same applied to five other scores concerning pain
and/or functional capacity. The beneficial effect was signifi-
cantly better for the KP group at each time point (1, 3, 6, and
12 months). Analgesic benefit and some functional benefits
were still higher in the KP group compared with the control
group after 24 months of follow-up [53]. There was no sig-
nificant difference in the occurrence of new radiological VFs
after 24 months of follow-up: 47.5 % in the KP group versus
44.1 % in the control group. Around 80 % of VFs occurred
during the first year. A prospective study comparing KP with
conservative treatment during the first 3 weeks following a
symptomatic VF showed that KP had an analgesic benefit
only during the first month after the procedure [54]. The
authors concluded that patients should be treated conserva-
tively before KP is considered.
Vertebroplasty versus kyphoplasty
There has been only one randomized controlled study com-
paring VP with KP for osteoporotic VFs. Liu et al. enrolled
100 patients presenting with a VF that had occurred less than
6 months before [55]. The time period between the VF and the
procedure was 17.0 days for KP and 15.8 days for VP. There
was an excellent analgesic effect in both groups, with no
significant difference. A reduction in the kyphosis angle was
observed in both groups, but it was significantly greater in the
KP group (P <0.001). More PMMAwas used in the KP group
than in the VP group (5.56±0.62 versus 4.91±0.65 mL, P <
0.001). Follow-up lasted 6 months, and there were two new
VFs, both of which occurred in the KP group. There have
been nine case series comparing VPwith KP, with between 45
and 154 patients enrolled in each [56-64]. The groups were
highly heterogeneous, making it very difficult to compare the
results. Mean age ranged from 62 to 78, and the duration of
follow-up varied between 6 and 42 months. When it was
mentioned, the volume of PMMA injected ranged from 2.5
to 5.8 mL in the VP groups and from 1.8 to 5.6 mL in the KP
group. An excellent meta-analysis comparing VP with KP has
recently been published [26]. In the 10 studies analyzed,
which encompassed 783 patients, there was no difference
between the VP and KP groups in terms of short- and long-
term analgesic effects or short- and long-term functional ben-
efits. Operation time was the same for both procedures. But
KP was superior to VP with regard to the following points:
long-term improvement of kyphosis angle (mean difference=
−2.64, 95 % CI, −4.66 to −0.61; P =0.01), improvement in
anterior height of vertebral body (mean difference=3.67 mm,
95 % CI, 1.40 to 5.94; P =0.002), and reduction in cement
leakage (RR=0.70, 95 % CI, 0.52 to 0.95; P =0.02). The risk
of a VF adjacent to the treated vertebra was 7.1 and 3.7 % for
the KP and VP groups, respectively, with no significant dif-
ference noted. It is not certain that a difference of 2° to 3° on
the kyphosis angle or an increase of 3 to 4 mm of the anterior
height of vertebral body will have a clinical relevance. To
answer this question, it is necessary to have a randomized
study with the kyphosis angle as primary endpoint.
Side effects and complications of vertebroplasty
and kyphoplasty
Main side effects
Complications are more common when VP/KP is performed
for metastatic VFs than when it is performed for osteoporotic
VFs. It is necessary to distinguish between asymptomatic side
effects, symptomatic side effects, and long-term complica-
tions. Asymptomatic side effects are associated with cement
leakage along the trocar route, in the epidural and intradiscal
regions, or with intravenous cement leakage. Cement leakage
is much less frequent with KP than VP [33, 65-68]. It may
concern up to 70 % of patients depending on the series and
study methods, but is most often neglected [69]. However,
some asymptomatic side effects are a cause of worry. In
VERTOS II, pulmonary embolisms were screened by chest
CTand found in 26% (95%CI, 16–39%) of patients [70]. All
the patients were asymptomatic. Cement leakage into the
azygos vein was the only risk factor identified for pulmonary
embolism (OR 43; 95 % CI, 5–396). The short-term symp-
tomatic side effects of VP/KP for osteoporotic VFs usually
concern between 1 and 3 % of patients, and seem to be even
less in more recent series. In Hulme’s review, the risk of
complications was 3.9 % after VP and 2.2 % after KP [65].
Leakage into the epidural space, spinal canal, or foramen may
cause medullary or spinal damage. Venous leakage may, in
rare cases, result in symptomatic pulmonary embolism. Infec-
tions and hematomas are very rare. Table 3 provides the main
side effects of these procedures, as well as their rate of occur-
rence. In an Italian series involving 4,547 patients who had
undergone at least one VP (of whom 73 % for osteoporosis),
the side effects observed were as follows: venous cement
leakage 930 (20.5 %), intradiscal cement leakage 490
(10.8 %), symptomatic pulmonary embolism 45 (1.0 %), ce-
ment leakage into spinal canal 5 (0.1 %), hematoma 2
(0.04 %), and infection 2 (0.04 %) [71]. For all these, side
effects should be taken into account the date of publication.
Indeed, the quality of biomaterials improves and operators
experience increases. This is particularly true for cement leak-
age, less frequently described in recent studies
Risk of new vertebral fracture
This risk was not analyzed in the first studies of VP/KP, since
osteoporotic vertebral fragility was in itself a strong risk factor
for refracture (Tables 3 and 4). What is more, in the studies,
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the radiological and clinical VFs have to be distinguished.
There does indeed seem to be an increased risk of subsequent
VF, in particular to the vertebrae adjacent to the percutaneous
procedure. Already in 2003, a series involving 177 patients
who had undergone VP reported the occurrence of 36 VFs in
22 (12.4%) of them [72]. Of these 36VFs, 24 (67%) occurred
in vertebral levels adjacent to the VP, and two thirds of the
VFs occurred in the first 30 days after the VP. A small series
published in 2004 showed an increased risk of adjacent VFs in
the first 2 months following KP [73]. In 2006, two new studies
described an increased risk of VF adjacent to the VP. In the
first series, the risk was 24 % (16/66) at 1 year [74]. These 16
patients suffered 26 new VFs, of which 50 % were in verte-
brae adjacent to the VP. Trout et al. retrospectively analyzed
the data of 432 patients who had undergone VP and been
followed up for 1 year [75]. A total of 186 new VFs occurred
in 86 patients (19.9 %), and in 41 % of these cases, the new
fractures were in vertebrae adjacent to the VP. Interestingly,
the adjacent VFs occurred earlier than the other fractures (58
versus 127 days, P <0.001). According to the author, this time
aspect appeared to indicate that mechanical forces acting
between the osteoporotic and cemented vertebrae were to
blame, and not the fact that osteoporotic VFs mostly occur
in particular spinal locations. However, Diamond et al. com-
pared a VP group with a control group and reported a similar
radiological refracture risk of 43 and 44 %, respectively [40].
Half of these new VFs were adjacent to the initial VF. In the
FREE trial, which compared KP with conventional treatment,
between 22 and 27 % of patients suffered a new radiological
VF at 3 months, 38% at 12 months, and between 44 and 48%
at 24 months, with no difference noted between the two
groups [53]. This was also the case in VERTOS II, in which
there was no difference in the risk of refracture at 1 year
between the two groups [76]. The only risk factor for a new
VF was the number of preexisting VFs. In the Italian
EVERESTcohort, the risk of new clinical VFs in osteoporosis
(maximum follow-up 12 months) was 13 %, of which 70 %
were immediately above or below the vertebra treated by VP
[71]. In the randomized study of Blasco et al., 29 new radio-
logical VFs were observed in 17/64 patients treated by VP,
whereas there were eight in 8/61 control patients [48]. Of
these VFs, 71 and 9 % were clinical in the VP and control
groups, respectively. The risk of new radiological VF was
2.78 higher (OR 2.78; 95 % CI, 1.02–7.62, P =0.046), and
the risk of new clinical VF was 25.67 higher (OR 25.67; 95 %
CI, 3.04–216.8, P =0.029), in the VP group compared with
the control group. Intradiscal cement leakage was more fre-
quently observed in patients with new VF (OR 7.17; 95 % CI,
1.69–30.42, P =0.008).
Table 3 Side effects and com-
plications of percutaneous
vertebroplasty or kyphoplasty
KP kyphoplasty, VF vertebral
fracture, VP vertebroplasty
Technique References
Asymptomatic side effects
Intervertebral disc cement leakage 10–27 % KP [51, 52, 68]
Intervertebral disc cement leakage 10–75 % VP [51, 68, 76]
Paravertebral veins cement leakage 20 % VP [71]
Asymptomatic pulmonary embolism 26 % VP [70]
Symptomatic side effects 1–3 % VP/KP [68, 71]
Neurological complications >1 % [36, 68, 71]
Infection >1 % [35, 67, 71]
Symptomatic pulmonary embolism ≤1 % [71]
Hematoma <1 % [52, 71]
Risk of secondary VF
Clinical VF at 12 months 13–27 % VP/KP [48, 68, 74, 75, 77]
Clinical VF at 24 months 21–27 % VP [69, 78]
Radiological VF at 12 months 30–38 % VP/KP [53, 79]
Radiological VF at 24 months 44–48 % KP [40, 53]
Table 4 Risk factors for new VF after percutaneous vertebroplasty or
kyphoplasty [47, 68, 76, 78, 79]
Strong risk factors
Patient-level risk factors
Age (>80 years)
Low bone mineral density (T-score<−3 DS) +
Low 25OH vitamin D (<20 ng/mL or<50 nmol/L)
Glucocorticoid therapy
Number of preexisting VF
Vertebra-level risk factors
Intervertebral disc cement leakage +
Short time from fracture to procedure +
Thoraco-lumbar localization +
Number of treated vertebrae
VF vertebral fracture
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In an Alabama cohort involving 212 patients who had
suffered a VF, 48 underwent VP/KP and 164 received con-
servative treatment [77]. The adjusted relative risk of suffering
a new radiological VF was 6.8 (1.7–26.9) at 3 months and 2.9
(1.1–7.9) at 12 months for the group treated by VP/KP. In a
series of 144 patients who had undergone VP and were
followed up for 2 years, the risk of new clinical VF was
27 %, of which 56 % adjacent to the vertebra treated [78].
The adjacent VFs occurred within 149 days, and the other VFs
within 367 days. Multivariate analysis showed that the risk
factors for a newVFwere the number of VPs, inhomogeneous
cement distribution, and a lowHounsfield unit value on CT. In
the randomized controlled study published by Blasco et al.,
multivariate analysis showed that the risk factors for a newVF
following VP were: 25 OH vitamin D level <20 ng/mL (RR
15,47, 95 % CI, 2.99–79.86), glucocorticoid therapy (RR
3.64, 95 % CI, 1.61–8.26), and age >80 years (RR 3.20,
95 % CI, 1.70–6.03) [48, 79]. The risk of suffering a new
radiological VFwasmodeled in a series of 115 patients having
undergone 216 VPs [80]. The probability of being fracture-
free at 1 year ranged from 98.3% (97.5–100) to 17.5% (1.17–
33.8) depending on the risk factors. Poor prognostic factors
were lowered bone mineral density (especially<−3 SD), the
severity of vertebral deformation, recent fracture, fracture in
the thoracolumbar junction, and intradiscal cement leakage.
There was a clear link between the volume of intradiscal
cement and refracture risk. In fractures adjacent to the vertebra
that was treated, mean intradiscal cement volume was
0.45 mL, compared with 0.21 mL in the group with no new
fractures (P <0.004). A systematic review included 24 obser-
vational studies published between 2004 and 2012 covering 3,
789 patients who had undergone 5,464 vertebroplasties [69].
Mean follow-up was 22.8 months. The risk of a new clinical
VFwas 25.5%. The authors identified three strong risk factors
for fracture recurrence (decreased bone mineral density,
intradiscal cement leakage, and vertebral height restoration)
and six moderate risk factors (old age, decreased BMI, num-
ber of existing VFs, number of VPs, cement leakage, and VP
of the thoracolumbar junction). There did not appear to be a
difference in the risk of refracture following either VP or KP
[26]. Table 4 summarizes the main risk factors for a new
vertebral fracture. Even though everyone recognizes that VF
is a strong risk factor for VF recurrence, it can clearly be seen
from the latest studies and analyses that VP/KP is an addi-
tional risk factor for new VFs. What is more, it would seem
that it may be possible to identify patients who are at high- or
low risk of recurrence.
Discussion
VF can be a painful event that has a significant impact on
quality of life and that does not always respond to the
available antalgic drug therapies. VP and KP are therefore
logical solutions in these refractory settings. What is more, the
fact that vertebral height can be partially or fully restored with
KP provides great hope that the loss of quality of life associ-
ated with vertebral height loss can be limited. Although the
case series that were initially published were all very encour-
aging, it must be recognized that the results of the randomized
studies have been very mixed. Moreover, randomized studies
are rare. When comparing VP with a sham-controlled group,
no benefit of VP was observed [35, 36, 45]. A potential effect
of local anesthesia on the level of pain may account for this.
For others, the volume of cement injected (mean cemented
vertebral body fraction) appeared to play a decisive role in
obtaining pain relief [81]. In the study by Buchbinder et al.,
the quantity of cement injected per vertebra was 2.0±1.2 mL
[35]. In the study by Kallmes et al., it was not mentioned [36].
In a series including 106 patients who had undergone 196
VPs, mean cemented vertebral body fraction was significantly
smaller in non-responders than in patients who experienced an
analgesic benefit (15 versus 21 %, P =0.002) [81]. The mean
volume injected was 3.94±1.89 mL (0.13–10.8 mL), but may
vary with vertebral level, severity of the fracture, and gender.
And indeed, injecting a bigger volume of PMMA increases
the risk of cement leakage, and so it may increase the risk of
symptomatic side effects and fracture recurrence [80]. Less
pressure is required for injecting the PMMA in KP, and the
risks of cement leakage are reduced [65, 66]. However, com-
paring VP with KP has not shown any difference in terms of
analgesic or functional benefits or risks of refracture [26].
KP’s benefit is that it limits vertebral height loss and kyphotic
angle, but without any impact on the various functional scores
used in the studies, usually with a follow-up period of
12 months. It is true that a potential longer term benefit
remains unknown. The only randomized controlled study
comparing KP with conservative management showed a con-
siderable analgesic and functional benefit that lasted at least
2 years [52, 53]. There is unfortunately only this one study,
and the control group was not sham-controlled.
It is difficult to compare the studies given the highly
diverse enrollment criteria and differing measurement tools
used. Moreover, the patient populations included in each of
the studies were limited in size. Patient age, number of VFs,
degree of the VF, time period between VF and VP/KP, volume
of PMMA injected, and injection pressure were all enrollment
and procedure parameters that varied from study to study.
Although pain evaluation is relatively well-standardized and
comparable, the tools for measuring functional status and
quality of life are extremely varied, and include everything
from instruments specifically for osteoporosis to very general
instruments. The EuroQol Group 5-Dimension Self-report
Questionnaire, SF-36 mental component standardized, SF-36
physical component standardized, Bartel Index, Oswestry
Disability Index, RDQ, modified RDQ, Qualeffo-41, and
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European Vertebral Osteoporosis Study questionnaire were
used to assess the functional improvement and quality of life
of patients. In spite of the limited clinical comparisons and
scepticism raised by this literature review, a recent meta-
analysis has shown greater pain relief, functional recovery,
and health-related quality of life with VP or KP compared
with controls [82]. VP or KP better results were significant at
both the early (<3 months) and late time points (6 to
12 months), and the risk of new VF was not statistically
different between the groups. One study has a large effect on
these results [47]. Of the eight existing randomized controlled
studies, that of Blasco et al. showing a significant increase in
the risk of new VF after VP was not included, and the study of
Rousing et al. was only included for certain analyses [41, 48].
What can we do with a patient with a painful VF in routine
clinical practice (Table 5)? The immediate analgesic benefit of
VP/KPmay be an advantage provided that the related risks are
low. But what is an acceptable time limit between the onset of
pain and performance of the procedure? In VERTOS II for
example, the time limit between the onset of pain and the
procedure had to be <6 weeks. Of the 431 patients who were
eligible for randomization, there was a complete disappear-
ance of pain before the performance of VP in 229 (53 %) of
them, who were therefore not included [46]. So should we
wait at least 6 weeks before suggestingVP/KP? And how long
can we wait before performing VP/KP? Does waiting a year
lead to a chance of success, as some authors affirm? A delay of
a year was seen as a cause of the absence of VP benefit in the
studies of Buchlinder and Kallmes [35, 36].
Patients with VF exhibit increased mortality rates. Could
performing VP/KP change this? Mc Donald et al. compared
524 patients who had undergone VP with 582 patients (371
asymptomatic, 201 symptomatic) with VF that was treated
conservatively [83]. The cohorts were followed up for be-
tween 3.7 and 5.4 years. Mortality was the same in the VP
group and control group with symptomatic VF. However,
mortality was higher in the VP group than in the control group
with asymptomatic VF. Estimated survival at 5 years was
56 % for the VP group, 61 % for the symptomatic group that
had not undergone VP, and 79 % for the asymptomatic group
that had not undergone VP. Another retrospective analysis
with a 2-year follow-up did not show any effect on mortality
[84]. Edidin et al. analyzed the mortality risk for operated and
non-operated VF patients in the Medicare population [85].
The authors identified 858,978 patients with osteoporotic VF
between 2005 and 2008, of whom 119,253 underwent KP and
63,693 VP. After 4 years of follow-up, 60.8 % of patients who
had undergone VP or KP were alive compared with 50.0 % of
patients who had not undergone any intervention (adjusted
Hazard Ratio [aHR]=0.63, P <0.001). The risk of death was
lower in the KP group than it was in the VP group (aHR=
0.77, P <0.001). We are faced with retrospective analyses
whose results are contradictory. Despite the various adjust-
ments that were made, the fact remains that the patients to
whom we propose a procedure are undoubtedly very different
from those to whom we do not propose this procedure.
Cost-effectiveness analyses allow both the advantages and
disadvantages of a procedure to be assimilated best, and may
be a solution with regard to the benefit of VP/KP. A few studies
have been conducted, and all are in favor of VP or KP compared
with conventional treatment [86-88]. The results of this study
type depend on which parameters are entered into the model. As
the benefits of VP/KP are debatable, it is too early for conducting
such studies. The results of a recent cost-effectiveness analysis
comparing VP with KP were contradictory [89].
Another decisive element is the necessity of rapidly initiating
a specific treatment for osteoporosis. Patients suffering from an
atraumatic VF have by definition osteoporosis and are at great
risk of refracture. Treatment is clearly indicated. In a cohort
study involving 9,238 patients who were hospitalized for an
osteoporotic VF, undergoing VP/KP increased the probability
of receiving an anti-osteoporosis therapy [90]. At 1 month
following the VF, 46 % of patients who had undergone VP/
KP were on anti-osteoporosis therapy, compared with 32 % of
patients who had not undergone VP/KP. At 6 months, the
respective results were 59 and 47 %. These results are already
better compared to clinical practice and could be further im-
proved in a randomized controlled trial or by clinical pathway.
In the FREE study, over the course of 12months, the number of
patients receiving calcium and vitamin D increased from
around 50 to 85 %, and the number of those receiving a
bisphosphonate increased from around 45 to 75 %, with no
difference noted between the VP and control groups [52].
Limitations and prospects for the future
Further randomized controlled studies of good quality are
warranted in order to better define the profile of patients
Table 5 Proposal for clinical management of symptomatic osteoporotic
vertebral fracture
Day 1 to day 28
1. Confirm the fracture by a lateral radiograph of the thoracolumbar
spine (or a CT scan if needed)
2. Give analgesics including nonsteroidal analgesics +/− morphine
derivatives
3. If the pain is not controlled, add calcitonine
4. Make an osteoporosis and fracture risk assessment
5. Initiate an anti-osteoporotic treatment (antiresorptive or anabolic)
with calcium and vitamin D
6. Reassess regularly the clinical course
Day 21 to day 42
1. In case of disabling pain, perform a MRI
2. Evaluate the indication for VP or KP
Osteoporos Int (2014) 25:807–819 815
who may benefit from VP or KP. VERTOS IV will attempt to
answer this question and is designed to include patients who
are 50 or older, have had a painful VF for less than 6 weeks,
and display edema onMRI scans. Patients will be randomized
for either VP or a sham intervention [91].
Many questions remain regarding the ideal biomate-
rials (offering the best biomechanical properties) and
best technique (material, injection pressure, or uni- or
bilateral approach) to be used. Mixing the cement with
a biocompatible liquid may improve the biomechanical
properties, thus reducing adjacent VFs. A reduction of
51 % in cement stiffness, which was obtained by adding
serum, may reduce the risk of refracture [92]. In a recent
randomized controlled trial, no beneficial effect of vertebral
body stenting over KP was found among patients with painful
osteoporotic VF [93]. In another randomized study, KIVA, a
new vertebral augmentation treatment system, yielded better
results than KP did for restoring vertebral body wedge defor-
mity, with less cement leakage [94]. In another recent study, a
unipedicular approach was recommended for KP rather than a
bipedicular one, the benefits obtained being the same [95].
These new techniques require further investigation.
Osteoporotic drug treatments are rarely mentioned in
the studies of VP/KP. All patients suffering from a VF
must be given calcium, vitamin D, and an anti-
osteoporotic treatment, ideally a bone anabolic agent,
on account of the severity of the underlying osteoporo-
sis. This treatment should be initiated before VP/KP is even
considered. What is more, VP/KP has never been compared
with optimal osteoporotic drug therapy. Such a clinical study
should comprise a randomized design with three arms: (1) VP
or KP only, (2) VP or KP with a bone anabolic agent, (3) bone
anabolic agent only.
Conclusion
The efficacy of VP/KP for controlling pain after VF is
still a matter of controversy. VP/KP should therefore be
reserved for VF patients when a properly managed
analgesic treatment has failed, without omitting to initi-
ate osteoporotic therapy. KP differs from VP in that it
enables better vertebral height restoration and thus ky-
photic angle reduction, but its costs are higher, while its
long-term benefit is not known. Recent studies clearly
show that both VP and KP increase the risk of new
VFs, in particular in the vertebrae adjacent to those
treated. These refractures occur within a relatively short
time period. Certain risk factors have been identified. It
seems therefore appropriate to involve the patients to
whom VP/KP is being proposed in the decision-making
process. Further randomized controlled studies of good
quality are necessary to better identify those patients
likely to benefit the most from these procedures.
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